The year gone by in international biotech
One drug towered over the rest in 2014, while the immuno-oncology and cardiovascular areas took center stage. MedWatch has turned its scrutinizing gaze to the year gone by in international biotech.
BY STEFAN SINGH KAILAY
With headlines like “Breakthrough in hepatitis battle”, “Gilead’s golden tuicket leaves rivals in its wake” and “Gilead could be sitting on the biggest blockbuster ever” Gilead Sciences hep C treatment Sovaldi – and later combo therapy Harvoni – has been the talk of biotech town in 2014, and Claus Henrik Johansen, senior portfolio manager in Danske Capital, believes the massive revenue generated by Sovaldi is one of the major surprises in the year gone by.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
